A pipeline of powerful possibilities.

Our dynamic portfolio of virology assets includes a pipeline focused on curing HBV. Today, we have several active clinical studies, including approaches combining different mechanisms of action to achieve our therapeutic goals.

Arbutus Powerful Pipeline

Lead Optimization

IND Enabling

Phase 1

Phase 2

Phase 3


RNAi Therapeutic

Imdusiran (AB-729) cHBV

AB-729-001 single-ascending dose / multiple-ascending dose

Imdusiran (AB-729) cHBV

AB-729-201 Combo trial (imdusiran + Peg-IFNa-2a + NA)

Imdusiran (AB-729) cHBV

AB-729-202 Combo trial (imdusiran + vaccine + NA )

PD-L1 Inhibitor


AB-101-001 single-ascending dose / multiple-ascending dose

All Arbutus clinical trials are conducted in compliance with the Declaration of Helsinki and the ICH Guideline for Good Clinical Practice

Suppress Reduce Boost


Learn about our three-pronged Suppress, Reduce, Boost approach to HBV.

Discover our HBV assets